The hybridoma revolution: an offshoot of basic research
The hybridoma revolution: an offshoot of basic research
复制标题
DOI：
10.1002/(sici)1521-1878(199911)21:11
复制
发表时间：
1999-11-01
期刊：
影响因子：
4
通讯作者：
Milstein, C
中科院分区：
文献类型：
--
作者：
Milstein, C
在这篇文章中，我描述了我对抗体多样性的本质和起源的兴趣如何引导我通过使用体细胞遗传技术来解决这个问题。第一个杂交瘤（一种由短寿命淋巴细胞和骨髓瘤细胞系融合而成的永生抗体分泌细胞系）就是这种方法的一个分支。尽管这项发明并不是用于这些目的，但很快就发现它在基础研究和工业中具有广泛的潜力。事实上，该技术为复杂生物物质的研究开辟了新的途径，并成为定义新分化标志物的首选方法。杂交瘤还使我们能够剖析对简单抗原的免疫应答，并证明体细胞突变在产生高亲和力抗体中的关键作用。现在，单克隆抗体可以在体外衍生和操作，导致治疗应用的重要新发展。BioEssays 1999;21：966-973. (C)John Wiley & Sons，Inc.
in this narrative, I describe how my interest in the nature and origin of antibody diversity led me to tackle the problem by using somatic cell genetic techniques. The first hybridoma (an immortal antibody-secreting cell line derived by fusion of a short-lived lymphocyte and a myeloma cell line) was an offshoot of this approach. Although not intended for such purposes, it soon became obvious that this invention had widespread potential in basic research and industry. Indeed, the technique opened new inroads into the study of complex biological substances and became the method of choice to define new differentiation markers. Hybridomas also allowed us to dissect the immune response to a simple antigen and to demonstrate the critical role of somatic mutations in the generation of high affinity antibodies. Now, monoclonal antibodies can be derived and manipulated in vitro, leading to important new developments in therapeutic applications. BioEssays 1999;21:966-973. (C) 1999 John Wiley & Sons, Inc.